![]() | Funda Meric Bernstam |
Prominent publications by Funda Meric Bernstam
BACKGROUND: The role of sentinel lymph node biopsy (SLNB) in patients with an initial diagnosis of ductal carcinoma in situ (DCIS) has not been well defined. The purpose of our study was to determine when the risk of finding invasive disease on final pathology in patients with an initial diagnosis of DCIS was sufficiently high to justify use of SLNB.
STUDY DESIGN: The records of 398 consecutive patients from our prospective database with an initial diagnosis of DCIS, treated between July ...
Also Ranks for: Initial Diagnosis | ductal carcinoma | slnb patients | invasive breast | sentinel lymph |
BACKGROUND: Neoadjuvant chemotherapy with trastuzumab for patients with HER2-positive breast cancer can produce a pathological complete response in the breast in 30-65% of patients. We investigated the effect of the timing of trastuzumab administration with anthracycline and taxane neoadjuvant chemotherapy.
METHODS: This randomised trial was done at 36 centres in the USA and Puerto Rico. Women with operable HER2-positive invasive breast cancer were randomly assigned (1:1) with a biased ...
Also Ranks for: Neoadjuvant Treatment | trastuzumab patients | positive breast | pathological complete response | 12 weeks |
PURPOSE: Rapamycin inhibits the serine-threonine kinase mammalian target of rapamycin (mTOR), blocking phosphorylation of p70 S6 kinase (S6K1) and 4E-binding protein 1 (4E-BP1) and inhibiting protein translation and cell cycle progression. Rapamycin and its analogues are currently being tested in clinical trials as novel-targeted anticancer agents. Although rapamycin analogues show activity in clinical trials, only some of the treated patients respond. The purpose of this study is to ...
Also Ranks for: Rapamycin Sensitivity | cancer cells | antineoplastic blotting | proteins cell | protein kinases |
BACKGROUND: We determined the incidence of positive sentinel lymph nodes (SLNs) in patients with ductal carcinoma in situ (DCIS) or microinvasive breast cancer (MIC) and the predictive factors of SLN metastasis in these patients.
METHODS: Of 4,503 patients who underwent SLN dissection between March 1994 and March 2006 at our institution, we identified those with a preoperative diagnosis or final diagnosis of DCIS or MIC. Clinicopathologic factors were examined by logistic regression ...
Also Ranks for: Patients Dcis | breast cancer | ductal carcinoma | preoperative diagnosis | sentinel lymph |
BACKGROUND: The feasibility and accuracy of sentinel lymph node (SLN) biopsy in patients with breast cancer after preoperative chemotherapy has been demonstrated in a number of large, single-institution studies. However, a relative contraindication to SLN biopsy after preoperative chemotherapy is the presence of axillary metastases at initial diagnosis. The objective of this study was to determine the feasibility and accuracy of SLN biopsy after preoperative chemotherapy in patients with ...
Also Ranks for: Node Biopsy | preoperative chemotherapy | axillary metastases | sentinel lymph | breast carcinoma |
BackgroundComplete axillary lymph node dissection (ALND) after a positive sentinel lymph node biopsy (SLNB) remains the standard practice. As nodal surgery has long been considered a staging procedure without a clear survival benefit, the need for ALND in all patients is debatable. The purpose of this study was to examine differences in survival for patients undergoing SLNB alone versus SLNB with complete ALND.MethodsPatients with breast cancer who underwent SLNB and were found to have ...
Also Ranks for: Node Biopsy | sentinel lymph | patients slnb | positive breast | seer database |
BACKGROUND: The axillary pathologic complete response rate (pCR) and the effect of axillary pCR on disease-free survival (DFS) was determined in patients with HER2-positive breast cancer and biopsy-proven axillary lymph node metastases who were receiving concurrent trastuzumab and neoadjuvant chemotherapy. The use of neoadjuvant chemotherapy is reported to result in pCR in the breast and axilla in up to 25% of patients. Patients achieving a pCR have improved DFS and overall survival. To ...
Also Ranks for: Axillary Lymph | concurrent trastuzumab | node metastases | patients pcr | preoperative chemotherapy |
BackgroundResidual tumor size after neoadjuvant chemotherapy is an important consideration in surgical planning. We examined the accuracy of the combination of mammography and sonography in predicting pathologic residual tumor size.MethodsTumor size was evaluated by physical examination, mammography, and sonography at diagnosis and before surgery in 162 breast cancer patients who received neoadjuvant chemotherapy. Agreement between the predicted and the pathologic responses and the ...
Also Ranks for: Neoadjuvant Chemotherapy | mammography sonography | breast carcinoma | physical examination | tumor size |
OBJECTIVE: Sentinel lymph node (SLN) surgery is widely used for nodal staging in early-stage breast cancer. This study was performed to evaluate the accuracy of SLN surgery for patients undergoing neoadjuvant chemotherapy versus patients undergoing surgery first.
SUMMARY BACKGROUND DATA: Controversy exists regarding the timing of SLN surgery in patients planned for neoadjuvant chemotherapy. Proponents of SLN surgery after chemotherapy prefer a single surgical procedure with potential for ...
Also Ranks for: Neoadjuvant Chemotherapy | sln surgery | axillary dissection | axilla breast | sentinel lymph node |
In vitro, EGFR inhibition, combined with the BRAF inhibitor vemurafenib, causes synergistic cytotoxicity for BRAFV600E metastatic colorectal cancer, further augmented by irinotecan. The safety and efficacy of vemurafenib, irinotecan, and cetuximab in BRAF-mutated malignancies are not defined. In this 3+3 phase I study, patients with BRAFV600E-advanced solid cancers received cetuximab and irinotecan with escalating doses of vemurafenib. Nineteen patients (18 with metastatic colorectal ...
Also Ranks for: Brafv600e Mutation | metastatic colorectal cancer | irinotecan cetuximab | vemurafenib combination | egfr inhibition |
INTRODUCTION: Breast cancers of different molecular subtypes have different survival rates. The goal of this study was to identify patients at high risk for local-regional recurrence according to response to neoadjuvant chemotherapy and surrogate markers of molecular subtypes in patients undergoing breast conserving therapy (BCT).
METHODS: Clinicopathologic data from 595 breast cancer patients who received neoadjuvant chemotherapy and BCT from 1997 to 2005 were identified. Estrogen ...
Also Ranks for: Neoadjuvant Chemotherapy | surrogate markers | breast conserving therapy | patients her2 | estrogen receptors |
BACKGROUND AND OBJECTIVE: Sentinel lymph node (SLN) metastasis size is an important predictor of non-SLN involvement. The goal of this study was to construct a nomogram incorporating SLN metastasis size to accurately predict non-SLN involvement in patients with SLN-positive disease.
METHODS: We identified 509 patients with invasive breast cancer with a positive SLN who underwent completion axillary lymph node dissection (ALND). Clinicopathologic data including age, tumor size, histology, ...
Also Ranks for: Node Metastasis | sentinel lymph | breast cancer | positive sln | external cohort |
PURPOSE: We previously developed a prognostic index that stratified patients treated with breast conservation therapy (BCT) after neoadjuvant chemotherapy into groups with different risks for local-regional recurrence (LRR). The purpose of this study was to compare the rates of LRR as a function of prognostic index score for patients treated with BCT or mastectomy plus radiation after neoadjuvant chemotherapy.
METHODS: We retrospectively analyzed 815 patients treated with neoadjuvant ...
Also Ranks for: Neoadjuvant Chemotherapy | bct mastectomy | regional recurrence | local neoplasm | prognostic score |
The effect of ethnicity on immediate reconstruction rates after mastectomy for breast cancer
[ PUBLICATION ]
BACKGROUND: Multiple factors may influence whether patients undergo immediate breast reconstruction along with mastectomy for breast cancer. The authors investigated whether ethnicity was an independent predictor of immediate breast reconstruction.
METHODS: The authors identified 1004 patients who underwent mastectomy for breast cancer during the period 2001-2002. The rates of immediate reconstruction among different ethnicities were evaluated using the chi-square test. Logistic ...
Also Ranks for: Reconstruction Rates | breast cancer | white women | african americans | ethnic groups |
Association between clinical characteristics and risk‐reduction interventions in women who underwent BRCA1 and BRCA2 testing
[ PUBLICATION ]
BACKGROUND: Women who are at increased risk for breast and ovarian cancers, especially BRCA1 and BRCA2 mutation carriers, face a myriad of risk-reduction options, including increased surveillance, chemoprevention, prophylactic oophorectomy, and prophylactic mastectomy. However, little is known about which clinical, demographic, or cancer-related factors are associated with risk-reduction interventions.
METHODS: The authors conducted a retrospective review of records for 554 women who had ...
Also Ranks for: Women Breast Cancer | brca2 testing | clinical characteristics | prophylactic mastectomy | risk breast |
Key People For Breast Cancer
Funda Meric Bernstam:Expert Impact
Concepts for whichFunda Meric Bernstamhas direct influence:Breast cancer, Neoadjuvant chemotherapy, Solid tumors, Breast carcinoma, Advanced solid tumors.
Funda Meric Bernstam:KOL impact
Concepts related to the work of other authors for whichfor which Funda Meric Bernstam has influence:Breast cancer, Neoadjuvant chemotherapy, Lymph node, Ductal carcinoma, Tumor cells, Precision medicine, Gene expression.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |